Michael L. Kranda
President & CEO
Michael Kranda has spent more than 20 years developing biotechnology platforms, products and companies, including protein therapeutics, small molecule drugs and drug discovery and development platforms. He sits on the board of directors of several companies including PTC Therapeutics.
Previously, Mr. Kranda served as the CEO, President and Director of Anesiva, a publicly-traded biotech company in South San Francisco, CA. Prior to joining Anesiva, Mr. Kranda led life science venture investments as Managing Director for Vulcan Capital. Mr. Kranda also was CEO of Oxford GlycoSciences, establishing it as the leading proteomics platform-based drug discovery company.
Prior to that, Mr. Kranda spent 12 years at Immunex (now Amgen) where he served as President and Chief Operating Officer.
Mr. Kranda holds a BA and an MBA from the University of Washington School of Business.